期刊文献+

重组人血管内皮抑制素联合顺铂胸腔灌注化疗治疗恶性胸腔积液的Meta分析 被引量:17

Recombinant human endostatin combined with cisplatin perfusion chemotherapy for malignant pleural effusions: a Meta-analysis
下载PDF
导出
摘要 目的系统评价重组人血管内皮抑制素(恩度)联合顺铂胸腔灌注化疗与顺铂单药胸腔灌注化疗治疗恶性胸腔积液的有效性与安全性。方法计算机检索Pub Med、The Cochrane Library、Web of Science、万方数据库、中国期刊全文数据库(CNKI)、中国科技期刊数据库(VIP),同时辅以手工检索,收集2005年至2015年比较恩度联合顺铂胸腔灌注化疗与顺铂单药胸腔灌注化疗治疗恶性胸腔积液的随机对照研究(RCT)。使用Cochrane系统评价指导手册5.0评价纳入的RCT质量,采用Rev Man 5.2软件进行Meta分析,以胸腔积液控制有效率、生活质量改善率、不良反应发生率为结局指标。结果本研究共纳入15项RCT,共936例患者。Meta分析结果显示,恩度联合顺铂组治疗的胸腔积液控制有效率(RR=1.54,95%CI:1.38~1.71,P〈0.000 01)、生活质量改善率(RR=1.61,95%CI:1.41~1.84,P〈0.000 01)均优于顺铂单药组,差异有统计学意义。两组在胃肠道反应、胸痛、发热、骨髓抑制、肝肾功能异常、乏力、心电图异常等不良反应的发生率方面,差异无统计学意义(P〉0.05)。结论恩度联合顺铂胸腔灌注化疗较顺铂单药能够明显提高恶性胸腔积液患者治疗的有效率和生活质量,且不增加毒副反应。 Objective To evaluate the efficacy and safety of recombinant human endostatin( Endostar) plus cisplatin perfusion chemotherapy versus cisplatin alone in the treatment of malignant pleural effusions. Methods Databases of Pub Med,The Cochrane Library,Web of Science,Wanfang,CNKI,VIP were searched and randomized controlled trials( RCTs) on endostar plus cisplatin versus cisplatin alone for malignant pleural effusions from 2005 to 2015 were collected. The quality of RCTs was assessed by Cochrane handbook 5. 0 and Meta-analysis was carried out by Rev Man 5. 2 software. Results A total of 15 RCTs involving 936 patients were included. Compared with the cisplatin alone group,the endostar plus cisplatin group had a higher effective rate of controlling malignant effusions( RR = 1. 54,95% CI: 1. 38-1. 71,P〈0. 000 01),better improvement in quality of life( RR = 1. 61,95% CI: 1. 41-1. 84,P〈0. 000 01). As for side effects,there were no significant differences between the two groups in the incidences of gastrointestinal reaction,chest pain,fever,myelosuppression,dysfunction of liver and kidney,fatigue,electrocardiographic abnormality. Conclusion Compared with cisplatin alone,endostar plus cisplatin can improve the efficacy and quality of life of patients with malignant pleural effusions without increasement of adverse reactions.
出处 《临床肿瘤学杂志》 CAS 2015年第12期1117-1123,共7页 Chinese Clinical Oncology
关键词 重组人血管内皮抑制素/恩度 恶性胸腔积液 灌注化疗 META分析 Recombinant human endostatin(Endostar) Malignant pleural effusions Perfusion chemotherapy Meta-analysis
  • 相关文献

参考文献27

二级参考文献165

共引文献317

同被引文献209

引证文献17

二级引证文献138

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部